Gene editing vets launch Korro to convert RNA bases
Atlas, NEA launch Korro with new take on RNA base editing, trio of gene editing veterans
A trio of gene editing industry veterans have teamed up to launch Korro Bio as their second company developing antisense-based therapies in less than a year. Korro is creating a new CRISPR-independent version of RNA base editing that pairs antisense technology with an endogenous RNA-modifying enzyme to precisely swap single target bases.
The company launched on Monday with undisclosed funding from Atlas Venture and NEA, and a team led by co-founders Nessan Bermingham, Andrew Fraley and Jean-François Formela, who also co-founded Triplet Therapeutics Inc. last year. ...
BCIQ Company Profiles
BCIQ Target Profiles
CRISPR-associated protein 13a (Cas13a) (C2c2)